Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis

Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis

(2016) Nadia Valin et al.   BMC INFECTIOUS DISEASES

Executive summary of the consensus document on post-exposure prophylaxis against HIV, HBV and HCV in adults and children

(2016)   ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA

Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects

(2016) Srini Ramanathan et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection

(2016) Lorna Leal et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection

(2016) Lorna Leal et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV integrase inhibitors: a new era in the treatment of HIV

(2015) Jose Luis Blanco et al.   EXPERT OPINION ON PHARMACOTHERAPY

Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques

(2015) Ivana Massud et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)

(2015) Kerri J. Penrose et al.   JOURNAL OF INFECTIOUS DISEASES

Adherence to HIV postexposure prophylaxis

(2014) Nathan Ford et al.   AIDS

Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis

(2013) David T. Kuhar et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Raltegravir, Tenofovir DF, and Emtricitabine for Postexposure Prophylaxis to Prevent the Sexual Transmission of HIV

(2012) Kenneth H. Mayer et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Better Adherence with Once‐Daily Antiretroviral Regimens: A Meta‐Analysis

(2009) Jean‐Jacques Parienti et al.   CLINICAL INFECTIOUS DISEASES